Ákos Nemecz

Ákos Nemecz

Auto-generated profile, based on publicly available information

Ákos Nemecz

Biochemistry Department, Nicolaus Copernicus University in Torun, 87-100 Torun, Poland

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2023 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
QLQimeng Li
Qimeng Li
ÁNÁkos Nemecz
Ákos Nemecz
GAGabriel AYMÉ
Gabriel AYMÉ
GBGabrielle Dejean de la Bâtie
Gabrielle Dejean de la Bâtie
MPMarie S. Prevost
Marie S. Prevost
PCPierre-Jean Corringer
Pierre-Jean Corringer
The α7 nicotinic acetylcholine receptor (nAChR), a potential drug target for treating cognitive disorders, mediates communication between neuronal and non-neuronal cells. Although many competitive antagonists, agonists, and partial-agonists have been found and synthesized, they have not led to effective therapeutic treatments. In this context, small molecules acting as positive allosteric modulators binding outside the orthosteric, acetylcholine, site have attracted considerable interest. Two single-domain antibody fragments, C4 and E3, against the extracellular domain of the human α7-nAChR were generated through alpaca immunization with cells expressing a human α7-nAChR/mouse 5-HT3A chimera, and are herein described. They bind to the α7-nAChR but not to the other major nAChR subtypes, α4β2 and α3β4. E3 acts as a slowly associating positive allosteric modulator, strongly potentiating the acetylcholine-elicited currents, while not precluding the desensitization of the receptor. An E3–E3 bivalent construct shows similar potentiating properties but displays very slow dissociation kinetics conferring quasi-irreversible properties. Whereas, C4 does not alter the receptor function, but fully inhibits the E3-evoked potentiation, showing it is a silent allosteric modulator competing with E3 binding. Both nanobodies do not compete with α-bungarotoxin, localizing at an allosteric extracellular binding site away from the orthosteric site. The functional differences of each nanobody, as well as the alteration of functional properties through nanobody modifications indicate the importance of this extracellular site. The nanobodies will be useful for pharmacological and structural investigations; moreover, they, along with the extracellular site, have a direct potential for clinical applications.

27 April 2023 in The Journal of Physiology
Verified
Journal Article
Closed access
CRCatherine Van Renterghem
Catherine Van Renterghem
ÁNÁkos Nemecz
Ákos Nemecz
SDSandrine Delarue‐Cochin
Sandrine Delarue‐Cochin
DJDelphine Joseph
Delphine Joseph
PCPierre‐Jean Corringer
Pierre‐Jean Corringer

11 February 2024 in Physiological Reports
Verified
Journal Article
Open access
CRCatherine Van Renterghem
Catherine Van Renterghem
ÁNÁkos Nemecz
Ákos Nemecz
KMKarima Medjebeur
Karima Medjebeur
PCPierre‐Jean Corringer
Pierre‐Jean Corringer
Using the bacterial proton‐activated pentameric receptor‐channel Gloeobacter violaceus ligand‐gated ion channel (GLIC): (1) We characterize saturated, mono‐carboxylates as negative modulators of GLIC (as previously shown for crotonate; Alqazzaz et al., Biochemistry, 2016, 55, 5947). Butyrate and crotonate have indistinguishable properties regarding negative modulation of wt GLIC. (2) We identify a locus in the pre‐β5 strand (Loop Ω) whose mutation inverses the effect of the mono‐carboxylate crotonate from negative to positive modulation of the allosteric transitions, suggesting an involvement of the pre‐β5 strand in coupling the extracellular orthotopic receptor to pore gating. (3) As an extension to the previously proposed “in series” mechanism, we suggest that a orthotopic/orthosteric site—vestibular site—Loop Ω—β5‐β6 “sandwich”—Pro‐Loop/Cys‐Loop series may be an essential component of orthotopic/orthosteric compound‐elicited gating control in this pentameric ligand‐gated ion channel, on top of which compounds targeting the vestibular site may provide modulation.

3 June 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
DNDorota Nemecz
Dorota Nemecz
WNWeronika A. Nowak
Weronika A. Nowak
ÁNÁkos Nemecz
Ákos Nemecz
Pentameric ligand-gated ion channels provide rapid chemical-electrical signal transmission between cells in the central and peripheral nervous system. Their dysfunction is associated with many nervous system disorders. They are composed of five identical (homomeric receptors) or homologous (heteromeric receptors) subunits. VHH nanobodies, or single-chain antibodies, are the variable domain, VHH, of antibodies that are composed of the heavy chain only from camelids. Their unique structure results in many specific biochemical and biophysical properties that make them an excellent alternative to conventional antibodies. This Perspective explores the published VHH nanobodies which have been isolated against pentameric ligand-gated ion channel subfamilies. It outlines the genetic and chemical modifications available to alter nanobody function. An assessment of the available functional and structural data indicate that it is feasible to create therapeutic agents and impart, through their modification, a given desired modulatory effect of its target receptor for current stoichiometric-specific VHH nanobodies.

15 March 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
CRCatherine Van Renterghem
Catherine Van Renterghem
ÁNÁkos Nemecz
Ákos Nemecz
KMKarima Medjebeur
Karima Medjebeur
PCPierre-Jean Corringer
Pierre-Jean Corringer
The bacterial model GLIC remains one of the best known among pentameric ligand-gated ion channels (pLGICs), regarding their structure. GLIC is activated at low extracellular pH, but no agonist compound is known. Van Renterghem et al . (2023) showed that short-chain di-carboxylates potentiate GLIC activity, with strict dependence on two carboxylate binding pockets, previously characterized by crystallography (Sauguet et al ., 2013, Fourati et al ., 2015, 2020). An “in series” model was proposed, with compound binding at the inter-subunit pocket [homologous to the pLGICs orthotopic neutotransmitter binding site], and with involvement of the intra-subunit (or vestibular) pocket in coupling binding to gating. Here we characterize saturated, mono-carboxylates as negative modulators of GLIC, as previously shown for crotonate (Alqazzaz et al ., 2016). Butyrate and crotonate have indistinguishable properties regarding negative modulation of WT GLIC. However, a double mutation in the pre-β5 strand (Loop Ω) converts crotonate, as well as caffeate, but not butyrate, into positive modulators. We perform a mutational analysis of residue dependency in the two pockets, with the pre-β5 strand either intact or mutated. We propose that positive modulation requires stringent conditions, with integrity of both pockets, whereas negative modulation is less labile. The vestibular pocket may be involved as an accessory binding site leading to negative, but not positive modulation. We propose that the pre-β5 strand is involved in ligand-elicited modulation of GLIC gating, not in pHo-controlled gating. Possible involvement in Eukaryote pLGICs of regions corresponding to the vestibular pocket and the pre-β5 strand/Loop Ω is discussed. Key points summary: Using the bacterial proton-activated receptor-channel GLIC, we identify a locus in the pre-β5 strand (Loop Ω) whose mutation inverses the effect of the mono-carboxylate crotonate from negative to positive modulation of the allosteric transitions, suggesting an involvement of the pre-β5 strand in coupling the extracellular orthotopic receptor to pore gating in this pentameric ligand-gated ion channel. As an extension to the previously proposed “in series” mechanism, we suggest that a orthotopic/orthosteric site – vestibular site – Loop Ω – β5-β6 “sandwich” - Pro-Loop/Cys-Loop series may be an essential component of orthotopic/orthosteric compound-elicited gating control in this pentameric ligand-gated ion channel, on top of which compounds targeting the vestibular site may provide modulation.

3 June 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
DNDorota Nemecz
Dorota Nemecz
WNWeronika Nowak
Weronika Nowak
ÁNÁkos Nemecz
Ákos Nemecz